首页>
外国专利>
A NOVEL GENE BASED STRATEGY FOR THE TREATMENT OF PRIMARY AND METASTATIC CANCERS USING TRANSGENIC MESENCHYMAL STEM CELLS OR OTHER SOMATIC CELLS BY USE OF ENGINEERED DNA CASETTE COMPRISING OF SPECIFICALLY MODIFIED GENE TNFSF10 AND HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE.
A NOVEL GENE BASED STRATEGY FOR THE TREATMENT OF PRIMARY AND METASTATIC CANCERS USING TRANSGENIC MESENCHYMAL STEM CELLS OR OTHER SOMATIC CELLS BY USE OF ENGINEERED DNA CASETTE COMPRISING OF SPECIFICALLY MODIFIED GENE TNFSF10 AND HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE.
Disclosed are the methods and compositions relating to methods of creating clinically safe genetically modified mesenchymal stem cells derived from umbilical cord tissue/ Wharton’s jelly and or other sources including bone marrow, and cord blood, or creating clinically safe genetically modified somatic cells like lymphocytes enabled with a genetic safety switch such that the in-vivo administered cells can be eliminated at any time desired, along with elimination of adjacent cancer cells and such that the administered genetically enabled cells also secrete anti-cancer proteins or molecules of interest, leading to therapeutic efficacy against cancer and other illnesses. The genetic safety switch is composed of herpes simplex virus tyrosine kinase (HSV-tk) such that when ganciclovir is administered the said mesenchymal stem cells will undergo apoptosis. In addition, the enabled cells will also have therapeutic application of genetically modified Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The modified version of the TRAIL has potential utility in providing beneficial effects in primary as well as metastatic cancer from the primary cancer in a subject in need thereof.
展开▼
